Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSpondyloarthritis

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis

Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen
The Journal of Rheumatology August 2021, 48 (8) 1259-1267; DOI: https://doi.org/10.3899/jrheum.201088
Peter C. Taylor
1P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter C. Taylor
  • For correspondence: peter.taylor@kennedy.ox.ac.uk
Désirée van der Heijde
2D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Désirée van der Heijde
Robert Landewé
3R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Landewé
Shannon McCue
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue Cheng
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annelies Boonen
5A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annelies Boonen
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Data supplements

    • 201088DataSuppl.pdf
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 8
1 Aug 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Aug 2021, 48 (8) 1259-1267; DOI: 10.3899/jrheum.201088

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Aug 2021, 48 (8) 1259-1267; DOI: 10.3899/jrheum.201088
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
    • DATA AVAILABILITY
    • ONLINE SUPPLEMENT
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Keywords

ANKYLOSING SPONDYLITIS
APREMILAST
AUTOIMMUNE DISEASES
BIOLOGIC THERAPY
CLINICAL TRIALS

Related Articles

Cited By...

More in this TOC Section

  • Knowledge, Awareness, and Attitudes Regarding Axial Spondyloarthritis Among Nonrheumatology Physicians in the United States
  • Effect of Age on Active and Structural Magnetic Resonance Imaging Lesions in Sacroiliac Joints of Healthy Individuals and Patients With Nonspecific Back Pain
  • Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network
Show more Spondyloarthritis

Similar Articles

Keywords

  • ankylosing spondylitis
  • apremilast
  • autoimmune diseases
  • biologic therapy
  • clinical trials

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire